Pharmacologic resistance in prolactinoma patients

Pituitary

Volumn 8, Issue 1, 2005, Pages 43-52

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bromocriptine; Cabergoline; Dopamine; Prolactin; Prolactinoma; Resistance

Indexed keywords

AROMATASE INHIBITOR; BROMOCRIPTINE; CABERGOLINE; CLOMIFENE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GONADORELIN; GONADOTROPIN; GUANINE NUCLEOTIDE BINDING PROTEIN; NERVE GROWTH FACTOR; PERGOLIDE; PLACEBO; PROLACTIN; QUINAGOLIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; ERGOLINE DERIVATIVE;

ARTICLE; DRUG INHIBITION; DRUG MECHANISM; DRUG SUBSTITUTION; FERTILIZATION; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; INHIBITION KINETICS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN SYNTHESIS; PROLACTINOMA; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HYPOPHYSIS TUMOR; MALE; PATHOLOGY; REVIEW; SECRETION;

BROMOCRIPTINE; CELL PROLIFERATION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERGOLINES; ESTROGENS; FEMALE; HUMANS; MALE; PERGOLIDE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RECEPTORS, DOPAMINE D2;

EID: 33644870544     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-5085-2     Document Type: Article

References (111)

1. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin N Amer 2001;30:585-610.
2. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;65:19-27.
3. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogenesis and therapy. Curr Opin Obstet Gynecol 1994;6:393-397.
4. 2dopamine receptors produced by alternative RNA splicing. Nature 1989;342:926-929.
5. DeCamilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979;278:252-254.
6. Senogles SE. The D2 dopamine receptor isoforms signal through distinct G iα proteins to inhibit adenylyl cyclase. J Biol Chem 1994;269:23120-23127.
7. Rasolonjanahary R, Gerard C, Dufour MN, Homburger V, Enjalbert A, Guillon G. Evidence for a direct negative coupling between dopamine-D2 receptors and PLC by heterotrimeric Gi1/2 proteins in rat anterior pituitary cell membranes. Endocrinology 2002;143:747-754.
8. 2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 1988;263:10127-10134.
9. o-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem 2002;277:35819-35825.
10. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E. Control of lactotroph proliferation by dopamine: Essential role of signaling through D2 receptors and ERKS. PNAS 2002;99:14530-14535.
11. Tindall GT, Kovacs Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178-1183.
12. Bassetti M, Spada A, Pezzo G, Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: A morphometric study. J Clin Endocrinol Metab 1984;58:268-273.
13. Stefaneanu L, Kovacs K, Scheithauer BW, Konogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocrine Pathol 2000;11:341-352.
14. Aoki MDP, Aoki A, Maldonado CA. Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol 2001;116:215-222.
15. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509.
16. Brue T, Pellegrini I, Gunz G, Morange I, DeWailly D, Brownell J, Enjalbert A, Jaquet P. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577-584.
17. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinomas intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454-456.
18. DiSarno A, Landi ML, Cappabianca P, DiSalle F, Rossi FW, Pivonello R, DiSomma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-5261.
19. Cannavó S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999;22:306-309.
20. Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG, Liuzzi A. Reenlargement of macroprolactinomas during bromocriptine treatment: Report of two cases. J Endocrinol Invest 1983;6:47-50.
21. Delgrange E, Crabbé J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250-253.
22. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: Effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;2962-2965.
23. Maurer RA. Estradiol regulates the transcription of the prolactin gene. J Biol Chem 1982;257:2133-2136.
24. Shull JD, Gorski J. Estrogen regulates the transcription of the rat prolactin gene in vivo through at least two independent mechanisms. Endocrinology 1985;116:2456-2462.
25. Lloyd GM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975;255:497-498.
26. Raymond V, Beaulieu M, Labrie F, Boissier J. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 1979;200:1173-1175.
27. West B, Dannies PS. Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. Endocrinology 1980;106:1108-1113.
28. Jaquet P, Gunz G, Grisoli F. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res 1985;22:153-163.
29. Heiman ML, Ben-Jonathan N. Rat anterior pituitary dopaminergic receptors are regulated by estradiol during lactation. Endocrinology 1982;111:1057-1060.
30. Pasqualini C, Bojda F, Kerdelhué B. Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomized rats. Endocrinology 1986;119:2484-2489.
31. Nansel DD, Gudelsky GA, Reymond MJ, Porter JC. Estrogen alters the responsiveness of the anterior pituitary gland to the actions of dopamine on lysosomal enzyme activity and prolactin release. Endocrinology 1981;108:903-907.
32. Páez-Pereda M, Giacomini D, Refojo D, Hagashima AC, Hopfner U, Grübler Y et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003;100:1034-1039.
33. Lamberts SWJ, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 1986;63:1342-1347.
34. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(Suppl):1121-1126.
35. Reyniak JV, Wenof M, Aubert JM, Stangel JJ. Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 1980;55:8-11.
36. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: A prospective study. Obstet Gynecol 1985;65:506.
37. Abu-Fadil S, DeVane G, Siler TM, Yen SS. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 1976;13:79-95.
38. Davis JRE, Selby C, Jeffcoate WJ. Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol 1984;20:427-434.
39. Hwang PLH, Ng CSA, Cheong ST. Effect of oral contraceptives on serum prolactin: A longitudinal study in 126 normal premenopausal women. Clin Endocrinol 1986;24:127-133.
40. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta H-J, Wilchins SA, Smith AC. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987;47:785-791.
41. DeLeo V, Lanzetta D, Vanni AL, D'Antona D, Severi FM. Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 1991;44:155-161.
42. Grasso A, Baraghini F, Barbieri C, et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 1982;4:19-26.
43. Perrone G, Falaschi P, Capri O, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 1994;39:202-207.
44. Castel-Branco C, Martínez de Osaba MJ, Fortuny A, Iglesias X, González-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995;40:556-560.
45. Foth D, Römer T. Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 1997;44:124-126.
46. Schlegel W, Petersdorf LI, Juner R, Schulte H, Ebert C, von Eckardstein A. The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women. Clin Endocrinol 1999;51:643-651.
47. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671-673.
48. Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998;58:69-73.
49. Fahy UM, Foster PA, Torode HW, Hartog M, Hull MGR. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992;6:183-188.
50. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. Arch Pathol Lab Med 1994;118:562.
51. Garcia MM, Kapcala LP. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995;18:450-455.
52. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 1987;64:391-394.
53. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002;87:4447-4451.
54. Fossati P, Strauch G, Tournaiaire J. Etude de l'activité de la bromocriptine dans les états d'hyperprolactinémie. Nouv Presse Med 1976;5:1687-1691.
55. Friesen HG, Tolis G. The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: The Canadian Cooperative Study. Clin Endocrinol 1977;6(Suppl):91s-99s.
56. Bergh T, Nillius SJ, Wide L. Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol 1978;88:435-451.
57. Badano AR, Miechi HR, Mirkin A, Arcángeli OA, Aparicio NJ, Rodríguez A, Oliva A, Turner D, Casas PRF. Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Fertil Steril 1979;31:124-128.
58. Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonanza D, Scarduelli C, Spelta B. Treatment of hyperprolactinemic states with different drugs: A study with bromocriptine, metergoline, and lisuride. Fertil Steril 1982;37:61-67.
59. Horowitz BL, Hamilton DJ, Sommers CJ, Bryan RN, Boyd AE III. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. AJNR 1983;4:415-417.
60. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698-705.
61. Liuzzi A, Dallabonzana D, Giuseppe MD, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656-659.
62. Van der Heijden PFM, de Wit W, Brownell J, Schoemaker J, Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 1991;40:111-118.
63. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 1992;38:84-89.
64. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909.
65. Pascal-Vigneron V, Weryha G, Bose M, Leclere J. Hyperprolactinemic amenorrhea: Treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995;24:754-757.
66. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053-3057.
67. Sabancu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 2001;40:857-861.
68. Essais O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, et al. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol 2002;63:524-531.
69. Kleinberg DL, Boyd AE III, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704-709.
70. L'Hermite M, Debusschere PM, Gillet C, Deschepper C. Treatment of hyperprolactinaemic patients with pergolide. Acta Endocrinol 1983;103:441-445.
71. Freda PU, Andreadis CI, Knandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8-13.
72. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286.
73. Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:684-686.
74. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US. Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731.
75. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
76. Ferrari C, Mattei A, Melis GB, et al. Cabergoline: Long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201-1206.
77. Ferrari C, Paracchi A, Mattei AM, de Vincentils S, D'Alberton A, Crosignani PG. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489-494.
78. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537-546.
79. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
80. Colao A, DiSarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, DiSalle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2246-2252.
81. Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026-1033.
82. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinol 1994;60:314-322.
83. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A. Alteration of Gα subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996;8:737-746.
84. Ahmed SR, Shalet SM. Discordant responses of prolactinomas to two different dopamine agonists. Clin Endocrinol 1986;24:421-426.
85. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991;27:375-379.
86. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM. Effect of the new dopaminergic agonist CV205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol 1991;34:25-29.
87. Razzaq R, O'Halloran DJ, Beardwell CG, Shalet SM. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res 1993;39:218-222.
88. Merola B, Sarnacchiaro F, Colao A, DiSomma C, DiSarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C, Lombardi G. Positive response to compound CV205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175-181.
89. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413-420.
90. Rohmer V, Freneau E, Morange I, Simonetta C, and Le Club de l'Hypophyse. Efficiency of quinagolide in resistance to ergot-derived dopamine agonists: Results of a multicenter study. Ann Endocrinol 2000;61:411-417.
91. Colao A, DiSarno A, Sarnacchiaro F, Ferone D, DiRenzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-883.
92. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212.
93. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, Schechtman E, Korczyn AD. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788.
94. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JFM, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R, and the PKDS009 Collaborative Study Group. Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
95. Radwanska E, McGarrigle HH, Little V, Lawrence D, Saris S, Swyer GI. Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin or bromocriptine. Fertil Steril 1979;32:187-192.
96. Crosignani PG, Ferrari C, Scarduelli C, Picciotti MC, Caldara R, Malinverni A. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 1981;58:708-713.
97. Leyendecker G, Sruve T, Plotz EJ. Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol 1980;229:177-190.
98. De Quijada M, Timmermans HAT, Lamberts SWJ. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. J Endocrinol 1980;86:109-116.
99. Nagy I, Valdenegro CA, MacLeod RM. Effect of antiestrogens on pituitary prolactin production in normal and pituitary tumor-bearing rats. Neuroendocrinology 1980;30:389-395.
100. Stalldecker G, Reynoso R, Piroli G, Cáceres N, DeNicola AF. Effects of dopamine and tamoxifen on serum prolactin and nuclear estrogen receptors in rat anterior pituitaries. Neuroendocrinol Lett 1993;15:389-395.
101. Lamberts SWJ, Verleun T, Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 1982;34:339-342.
102. Volker W, Gehring WG, Berning R, Schmidt RC, Schneider J, von zur Mühlen A. Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 1982;101:491-500.
103. Koizumi K, Aono T. Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 1986;46:312-314.
104. Yamashita M, Hirakawa T, Tashiro Y, Matsuda T, Kibe M, Fukushima T, et al. Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine. No Shinkei Geka 1987;15:65-72.
105. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E. Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats. Neuroscience Lett 2001;311:149-152.
106. Lasco A, Cannavó S, Gaudio A, Morabito N, Basile G, Nicita-Mauro V, Frisina N. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur J Endocrinol 2002;147:461-465.
107. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, dal Toso R, Balsari A, Spano PF. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90:7961-7965.
108. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF. Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas. Brit J Cancer 1995;72:1397-1399.
109. Fiorentini C, Guerra N, Facchetti M, Finardi A, Tiberio L, Schiaffonati L, Spano P, Missale C. Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75 NGFR-mediated activation of nuclear factor-κB. Mol Endocrinol 2002;16:353-366.
110. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Guiliani M, Stevens JC, Barbano R, Dyck PJ for the rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000;284:2215-2221.
111. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC, and the AIDS Clinical Trials Group Team 291. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001;57:1313-1316.